RxDoctor Payments Data

Steven Spencer, MD

Family Medicine · Katy, TXNPI 1134161367

Payments from drug & device makers

$4,396in general payments, 2019–2025

Across 249 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$715
  • Novo Nordisk$439
  • Amarin Pharma, Inc.$321
  • AbbVie$303
  • Merz North America, Inc.$268
  • Abbott$242
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,33199%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,396 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,697
Medicare patients
83
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$73,345
MounjaroTirzepatide17$25,283
JanuviaSitagliptin Phosphate11$17,016
FarxigaDapagliflozin Propanediol13$15,186
EliquisApixaban12$12,460
Rosuvastatin Calcium117$1,687
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide17$1,469
Testosterone Cypionate22$1,294
Levothyroxine Sodium115$1,233
SynthroidLevothyroxine Sodium21$1,218
Pravastatin Sodium46$1,049
Eszopiclone13$836
Bisoprolol Fumarate30$804
Amlodipine Besylate95$792
Tamsulosin Hcl27$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$439$73,34561 claims
Lilly USA, LLCMounjaro$209$25,28317 claims
MerckJanuvia$90$17,01611 claims
AstraZenecaFarxiga$715$15,18613 claims
PfizerEliquis$220$12,46012 claims
AbbVieSynthroid$303$1,21821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →